The top related signatures for Xuesaitong injection and stroke model on each scale
| Scale name . | Signature description . | Model CS/TCS . | XST CS/TCS . | Model NCS . | XST NCS . | Model P-value . | XST P-value . | Model FDR . | XST FDR . |
|---|---|---|---|---|---|---|---|---|---|
| Tissue | Brain | −1.08 | 0.91 | −15.27 | 12.35 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cell | Microglial cell | 0.49 | −0.36 | 11.45 | −8.42 | 0.00 | 0.00 | 0.00 | 0.00 |
| Macrophage | 0.65 | −0.55 | 10.20 | −8.35 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Lymphoid cell | −0.56 | 0.47 | −13.84 | 11.26 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Neuron | −0.65 | 0.45 | −14.63 | 10.53 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Pathological process | Necrobiotic xanthogranuloma | 0.55 | −0.52 | 9.06 | −8.45 | 0.00 | 0.00 | 0.00 | 0.00 |
| Visceral prolapse | 0.46 | −0.36 | 8.67 | −6.69 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inflammation | 0.16 | −0.12 | 8.67 | −6.36 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Nephrogenic fibrosing dermopathy | 0.55 | −0.45 | 8.40 | −7.21 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Serositis | 0.51 | −0.39 | 8.19 | −6.19 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Granuloma, plasma cell | 0.52 | −0.47 | 8.11 | −7.61 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Uterine prolapse | 0.45 | −0.37 | 8.06 | −6.51 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Bisphosphonate-associated osteonecrosis of the jaw | 0.41 | −0.33 | 7.94 | −6.64 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Granuloma, respiratory tract | 0.41 | −0.32 | 7.61 | −5.87 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Granuloma annulare | 0.49 | −0.45 | 7.52 | −6.97 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Pathway | Coronavirus disease – COVID-19 | 0.39 | −0.21 | 5.61 | −2.96 | 0.00 | 0.00 | 0.00 | 0.00 |
| Glutamatergic synapse | −0.42 | 0.31 | −4.95 | 3.65 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Circadian entrainment | −0.39 | 0.33 | −4.25 | 3.47 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Neuroactive ligand–receptor interaction | −0.22 | 0.16 | −4.19 | 3.16 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Ribosome | 0.36 | −0.38 | 4.07 | −4.18 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cytokine–cytokine receptor interaction | 0.25 | −0.19 | 4.05 | −2.96 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NF-kappa B signaling pathway | 0.36 | −0.19 | 3.91 | −2.01 | 0.00 | 0.00 | 0.00 | 0.02 | |
| NOD-like receptor signaling pathway | 0.30 | −0.14 | 3.88 | −1.81 | 0.00 | 0.01 | 0.00 | 0.04 | |
| Measles | 0.32 | −0.15 | 3.88 | −1.80 | 0.00 | 0.03 | 0.00 | 0.04 | |
| Cholinergic synapse | −0.32 | 0.25 | −3.76 | 2.94 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Biological process | Synaptic signaling | −0.36 | 0.25 | −8.97 | 6.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Chemical synaptic transmission | −0.37 | 0.25 | −8.90 | 5.92 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Anterograde trans-synaptic signaling | −0.37 | 0.25 | −8.86 | 6.05 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trans-synaptic signaling | −0.36 | 0.25 | −8.75 | 5.92 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cell activation | 0.27 | −0.20 | 8.50 | −6.07 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Immune effector process | 0.28 | −0.17 | 8.27 | −5.02 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Leukocyte activation | 0.27 | −0.19 | 8.08 | −5.79 | 0.00 | 0.00 | 0.00 | 0.00 | |
| myeloid leukocyte activation | 0.31 | −0.22 | 7.56 | −5.48 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Leukocyte-mediated immunity | 0.29 | −0.21 | 7.47 | −5.44 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Response to cytokine | 0.26 | −0.11 | 7.31 | −3.20 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Target | NCOR2 | −0.74 | 0.63 | −10.48 | 8.85 | 0.00 | 0.00 | 0.00 | 0.01 |
| JOSD1 | −0.60 | 0.56 | −8.73 | 8.12 | 0.00 | 0.00 | 0.00 | 0.00 | |
| GDI1 | −0.60 | 0.54 | −8.46 | 7.29 | 0.00 | 0.00 | 0.00 | 0.00 | |
| E2F6 | 0.58 | −0.48 | 8.34 | −6.87 | 0.00 | 0.00 | 0.01 | 0.00 | |
| IQGAP1 | −0.61 | 0.52 | −8.29 | 7.68 | 0.00 | 0.00 | 0.00 | 0.00 | |
| LARS | −0.55 | 0.55 | −8.16 | 7.77 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FAM69A | −0.56 | 0.41 | −8.15 | 6.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ACO2 | −0.57 | 0.47 | −8.11 | 6.62 | 0.00 | 0.00 | 0.00 | 0.00 | |
| RNF186 | −0.59 | 0.55 | −8.09 | 7.65 | 0.00 | 0.00 | 0.00 | 0.00 | |
| HGS | −0.56 | 0.47 | −7.95 | 6.42 | 0.00 | 0.00 | 0.00 | 0.00 |
| Scale name . | Signature description . | Model CS/TCS . | XST CS/TCS . | Model NCS . | XST NCS . | Model P-value . | XST P-value . | Model FDR . | XST FDR . |
|---|---|---|---|---|---|---|---|---|---|
| Tissue | Brain | −1.08 | 0.91 | −15.27 | 12.35 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cell | Microglial cell | 0.49 | −0.36 | 11.45 | −8.42 | 0.00 | 0.00 | 0.00 | 0.00 |
| Macrophage | 0.65 | −0.55 | 10.20 | −8.35 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Lymphoid cell | −0.56 | 0.47 | −13.84 | 11.26 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Neuron | −0.65 | 0.45 | −14.63 | 10.53 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Pathological process | Necrobiotic xanthogranuloma | 0.55 | −0.52 | 9.06 | −8.45 | 0.00 | 0.00 | 0.00 | 0.00 |
| Visceral prolapse | 0.46 | −0.36 | 8.67 | −6.69 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inflammation | 0.16 | −0.12 | 8.67 | −6.36 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Nephrogenic fibrosing dermopathy | 0.55 | −0.45 | 8.40 | −7.21 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Serositis | 0.51 | −0.39 | 8.19 | −6.19 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Granuloma, plasma cell | 0.52 | −0.47 | 8.11 | −7.61 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Uterine prolapse | 0.45 | −0.37 | 8.06 | −6.51 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Bisphosphonate-associated osteonecrosis of the jaw | 0.41 | −0.33 | 7.94 | −6.64 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Granuloma, respiratory tract | 0.41 | −0.32 | 7.61 | −5.87 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Granuloma annulare | 0.49 | −0.45 | 7.52 | −6.97 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Pathway | Coronavirus disease – COVID-19 | 0.39 | −0.21 | 5.61 | −2.96 | 0.00 | 0.00 | 0.00 | 0.00 |
| Glutamatergic synapse | −0.42 | 0.31 | −4.95 | 3.65 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Circadian entrainment | −0.39 | 0.33 | −4.25 | 3.47 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Neuroactive ligand–receptor interaction | −0.22 | 0.16 | −4.19 | 3.16 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Ribosome | 0.36 | −0.38 | 4.07 | −4.18 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cytokine–cytokine receptor interaction | 0.25 | −0.19 | 4.05 | −2.96 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NF-kappa B signaling pathway | 0.36 | −0.19 | 3.91 | −2.01 | 0.00 | 0.00 | 0.00 | 0.02 | |
| NOD-like receptor signaling pathway | 0.30 | −0.14 | 3.88 | −1.81 | 0.00 | 0.01 | 0.00 | 0.04 | |
| Measles | 0.32 | −0.15 | 3.88 | −1.80 | 0.00 | 0.03 | 0.00 | 0.04 | |
| Cholinergic synapse | −0.32 | 0.25 | −3.76 | 2.94 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Biological process | Synaptic signaling | −0.36 | 0.25 | −8.97 | 6.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Chemical synaptic transmission | −0.37 | 0.25 | −8.90 | 5.92 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Anterograde trans-synaptic signaling | −0.37 | 0.25 | −8.86 | 6.05 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trans-synaptic signaling | −0.36 | 0.25 | −8.75 | 5.92 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cell activation | 0.27 | −0.20 | 8.50 | −6.07 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Immune effector process | 0.28 | −0.17 | 8.27 | −5.02 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Leukocyte activation | 0.27 | −0.19 | 8.08 | −5.79 | 0.00 | 0.00 | 0.00 | 0.00 | |
| myeloid leukocyte activation | 0.31 | −0.22 | 7.56 | −5.48 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Leukocyte-mediated immunity | 0.29 | −0.21 | 7.47 | −5.44 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Response to cytokine | 0.26 | −0.11 | 7.31 | −3.20 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Target | NCOR2 | −0.74 | 0.63 | −10.48 | 8.85 | 0.00 | 0.00 | 0.00 | 0.01 |
| JOSD1 | −0.60 | 0.56 | −8.73 | 8.12 | 0.00 | 0.00 | 0.00 | 0.00 | |
| GDI1 | −0.60 | 0.54 | −8.46 | 7.29 | 0.00 | 0.00 | 0.00 | 0.00 | |
| E2F6 | 0.58 | −0.48 | 8.34 | −6.87 | 0.00 | 0.00 | 0.01 | 0.00 | |
| IQGAP1 | −0.61 | 0.52 | −8.29 | 7.68 | 0.00 | 0.00 | 0.00 | 0.00 | |
| LARS | −0.55 | 0.55 | −8.16 | 7.77 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FAM69A | −0.56 | 0.41 | −8.15 | 6.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ACO2 | −0.57 | 0.47 | −8.11 | 6.62 | 0.00 | 0.00 | 0.00 | 0.00 | |
| RNF186 | −0.59 | 0.55 | −8.09 | 7.65 | 0.00 | 0.00 | 0.00 | 0.00 | |
| HGS | −0.56 | 0.47 | −7.95 | 6.42 | 0.00 | 0.00 | 0.00 | 0.00 |
The top related signatures for Xuesaitong injection and stroke model on each scale
| Scale name . | Signature description . | Model CS/TCS . | XST CS/TCS . | Model NCS . | XST NCS . | Model P-value . | XST P-value . | Model FDR . | XST FDR . |
|---|---|---|---|---|---|---|---|---|---|
| Tissue | Brain | −1.08 | 0.91 | −15.27 | 12.35 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cell | Microglial cell | 0.49 | −0.36 | 11.45 | −8.42 | 0.00 | 0.00 | 0.00 | 0.00 |
| Macrophage | 0.65 | −0.55 | 10.20 | −8.35 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Lymphoid cell | −0.56 | 0.47 | −13.84 | 11.26 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Neuron | −0.65 | 0.45 | −14.63 | 10.53 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Pathological process | Necrobiotic xanthogranuloma | 0.55 | −0.52 | 9.06 | −8.45 | 0.00 | 0.00 | 0.00 | 0.00 |
| Visceral prolapse | 0.46 | −0.36 | 8.67 | −6.69 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inflammation | 0.16 | −0.12 | 8.67 | −6.36 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Nephrogenic fibrosing dermopathy | 0.55 | −0.45 | 8.40 | −7.21 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Serositis | 0.51 | −0.39 | 8.19 | −6.19 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Granuloma, plasma cell | 0.52 | −0.47 | 8.11 | −7.61 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Uterine prolapse | 0.45 | −0.37 | 8.06 | −6.51 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Bisphosphonate-associated osteonecrosis of the jaw | 0.41 | −0.33 | 7.94 | −6.64 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Granuloma, respiratory tract | 0.41 | −0.32 | 7.61 | −5.87 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Granuloma annulare | 0.49 | −0.45 | 7.52 | −6.97 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Pathway | Coronavirus disease – COVID-19 | 0.39 | −0.21 | 5.61 | −2.96 | 0.00 | 0.00 | 0.00 | 0.00 |
| Glutamatergic synapse | −0.42 | 0.31 | −4.95 | 3.65 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Circadian entrainment | −0.39 | 0.33 | −4.25 | 3.47 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Neuroactive ligand–receptor interaction | −0.22 | 0.16 | −4.19 | 3.16 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Ribosome | 0.36 | −0.38 | 4.07 | −4.18 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cytokine–cytokine receptor interaction | 0.25 | −0.19 | 4.05 | −2.96 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NF-kappa B signaling pathway | 0.36 | −0.19 | 3.91 | −2.01 | 0.00 | 0.00 | 0.00 | 0.02 | |
| NOD-like receptor signaling pathway | 0.30 | −0.14 | 3.88 | −1.81 | 0.00 | 0.01 | 0.00 | 0.04 | |
| Measles | 0.32 | −0.15 | 3.88 | −1.80 | 0.00 | 0.03 | 0.00 | 0.04 | |
| Cholinergic synapse | −0.32 | 0.25 | −3.76 | 2.94 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Biological process | Synaptic signaling | −0.36 | 0.25 | −8.97 | 6.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Chemical synaptic transmission | −0.37 | 0.25 | −8.90 | 5.92 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Anterograde trans-synaptic signaling | −0.37 | 0.25 | −8.86 | 6.05 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trans-synaptic signaling | −0.36 | 0.25 | −8.75 | 5.92 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cell activation | 0.27 | −0.20 | 8.50 | −6.07 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Immune effector process | 0.28 | −0.17 | 8.27 | −5.02 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Leukocyte activation | 0.27 | −0.19 | 8.08 | −5.79 | 0.00 | 0.00 | 0.00 | 0.00 | |
| myeloid leukocyte activation | 0.31 | −0.22 | 7.56 | −5.48 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Leukocyte-mediated immunity | 0.29 | −0.21 | 7.47 | −5.44 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Response to cytokine | 0.26 | −0.11 | 7.31 | −3.20 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Target | NCOR2 | −0.74 | 0.63 | −10.48 | 8.85 | 0.00 | 0.00 | 0.00 | 0.01 |
| JOSD1 | −0.60 | 0.56 | −8.73 | 8.12 | 0.00 | 0.00 | 0.00 | 0.00 | |
| GDI1 | −0.60 | 0.54 | −8.46 | 7.29 | 0.00 | 0.00 | 0.00 | 0.00 | |
| E2F6 | 0.58 | −0.48 | 8.34 | −6.87 | 0.00 | 0.00 | 0.01 | 0.00 | |
| IQGAP1 | −0.61 | 0.52 | −8.29 | 7.68 | 0.00 | 0.00 | 0.00 | 0.00 | |
| LARS | −0.55 | 0.55 | −8.16 | 7.77 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FAM69A | −0.56 | 0.41 | −8.15 | 6.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ACO2 | −0.57 | 0.47 | −8.11 | 6.62 | 0.00 | 0.00 | 0.00 | 0.00 | |
| RNF186 | −0.59 | 0.55 | −8.09 | 7.65 | 0.00 | 0.00 | 0.00 | 0.00 | |
| HGS | −0.56 | 0.47 | −7.95 | 6.42 | 0.00 | 0.00 | 0.00 | 0.00 |
| Scale name . | Signature description . | Model CS/TCS . | XST CS/TCS . | Model NCS . | XST NCS . | Model P-value . | XST P-value . | Model FDR . | XST FDR . |
|---|---|---|---|---|---|---|---|---|---|
| Tissue | Brain | −1.08 | 0.91 | −15.27 | 12.35 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cell | Microglial cell | 0.49 | −0.36 | 11.45 | −8.42 | 0.00 | 0.00 | 0.00 | 0.00 |
| Macrophage | 0.65 | −0.55 | 10.20 | −8.35 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Lymphoid cell | −0.56 | 0.47 | −13.84 | 11.26 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Neuron | −0.65 | 0.45 | −14.63 | 10.53 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Pathological process | Necrobiotic xanthogranuloma | 0.55 | −0.52 | 9.06 | −8.45 | 0.00 | 0.00 | 0.00 | 0.00 |
| Visceral prolapse | 0.46 | −0.36 | 8.67 | −6.69 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inflammation | 0.16 | −0.12 | 8.67 | −6.36 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Nephrogenic fibrosing dermopathy | 0.55 | −0.45 | 8.40 | −7.21 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Serositis | 0.51 | −0.39 | 8.19 | −6.19 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Granuloma, plasma cell | 0.52 | −0.47 | 8.11 | −7.61 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Uterine prolapse | 0.45 | −0.37 | 8.06 | −6.51 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Bisphosphonate-associated osteonecrosis of the jaw | 0.41 | −0.33 | 7.94 | −6.64 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Granuloma, respiratory tract | 0.41 | −0.32 | 7.61 | −5.87 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Granuloma annulare | 0.49 | −0.45 | 7.52 | −6.97 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Pathway | Coronavirus disease – COVID-19 | 0.39 | −0.21 | 5.61 | −2.96 | 0.00 | 0.00 | 0.00 | 0.00 |
| Glutamatergic synapse | −0.42 | 0.31 | −4.95 | 3.65 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Circadian entrainment | −0.39 | 0.33 | −4.25 | 3.47 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Neuroactive ligand–receptor interaction | −0.22 | 0.16 | −4.19 | 3.16 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Ribosome | 0.36 | −0.38 | 4.07 | −4.18 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cytokine–cytokine receptor interaction | 0.25 | −0.19 | 4.05 | −2.96 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NF-kappa B signaling pathway | 0.36 | −0.19 | 3.91 | −2.01 | 0.00 | 0.00 | 0.00 | 0.02 | |
| NOD-like receptor signaling pathway | 0.30 | −0.14 | 3.88 | −1.81 | 0.00 | 0.01 | 0.00 | 0.04 | |
| Measles | 0.32 | −0.15 | 3.88 | −1.80 | 0.00 | 0.03 | 0.00 | 0.04 | |
| Cholinergic synapse | −0.32 | 0.25 | −3.76 | 2.94 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Biological process | Synaptic signaling | −0.36 | 0.25 | −8.97 | 6.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Chemical synaptic transmission | −0.37 | 0.25 | −8.90 | 5.92 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Anterograde trans-synaptic signaling | −0.37 | 0.25 | −8.86 | 6.05 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trans-synaptic signaling | −0.36 | 0.25 | −8.75 | 5.92 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cell activation | 0.27 | −0.20 | 8.50 | −6.07 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Immune effector process | 0.28 | −0.17 | 8.27 | −5.02 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Leukocyte activation | 0.27 | −0.19 | 8.08 | −5.79 | 0.00 | 0.00 | 0.00 | 0.00 | |
| myeloid leukocyte activation | 0.31 | −0.22 | 7.56 | −5.48 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Leukocyte-mediated immunity | 0.29 | −0.21 | 7.47 | −5.44 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Response to cytokine | 0.26 | −0.11 | 7.31 | −3.20 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Target | NCOR2 | −0.74 | 0.63 | −10.48 | 8.85 | 0.00 | 0.00 | 0.00 | 0.01 |
| JOSD1 | −0.60 | 0.56 | −8.73 | 8.12 | 0.00 | 0.00 | 0.00 | 0.00 | |
| GDI1 | −0.60 | 0.54 | −8.46 | 7.29 | 0.00 | 0.00 | 0.00 | 0.00 | |
| E2F6 | 0.58 | −0.48 | 8.34 | −6.87 | 0.00 | 0.00 | 0.01 | 0.00 | |
| IQGAP1 | −0.61 | 0.52 | −8.29 | 7.68 | 0.00 | 0.00 | 0.00 | 0.00 | |
| LARS | −0.55 | 0.55 | −8.16 | 7.77 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FAM69A | −0.56 | 0.41 | −8.15 | 6.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ACO2 | −0.57 | 0.47 | −8.11 | 6.62 | 0.00 | 0.00 | 0.00 | 0.00 | |
| RNF186 | −0.59 | 0.55 | −8.09 | 7.65 | 0.00 | 0.00 | 0.00 | 0.00 | |
| HGS | −0.56 | 0.47 | −7.95 | 6.42 | 0.00 | 0.00 | 0.00 | 0.00 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
